C4 Therapeutics (CCCC) Evercore ISI 8th Annual HealthCONx Conference summary

Clinical program updates

• Two active clinical programs: cemsidomide (IKZF1/3 degrader) and CFT8919 (EGFR L858R degrader) are progressing, with cemsidomide moving to the next phase early next year and CFT8919 in a phase one study in China.

• Cemsidomide phase one showed a 36% ORR overall, with 40% and 53% ORR at the two highest doses; two complete responses observed at 100 mcg.

• Safety profile for cemsidomide is favorable, with no discontinuations due to safety and only 6% dose reductions; most adverse events were not drug-related.

• 100% of patients were triple-class exposed, and 75% had prior CAR T or T-cell engager therapy; response rates were consistent across these subgroups.

• Cemsidomide's efficacy and safety profile compare favorably to mezigdomide, with a more refractory patient population and fewer neutropenic complications.

Regulatory and development plans

• No further phase one updates planned for cemsidomide; focus is on advancing to phase two, with an FDA meeting on dose alignment scheduled for later this month.

• A prior Type C meeting with the FDA provided feedback shaping current development plans.

• The upcoming global 4L+ study will enroll triple-class refractory patients, with a target ORR of around 40% to demonstrate significant improvement over the 20% background rate.

• Confidence in single-arm study approval is based on precedent, but regulatory risk remains due to evolving standards and agency personnel.

Commercial and financial outlook

• Pricing for cemsidomide is expected to be competitive with current market analogs, but specifics are not disclosed.

• Duration of response in late-line settings is currently 9.3 months, exceeding the typical six-month benchmark.

• Cash runway extends through the end of 2028, not including up to $40 million in potential milestone payments from partners over 2026–2027.

• Key data readouts from the phase two MOMENTUM study are expected by late 2027 (investigator assessment) and later in 2028 (central assessment).